These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 14686229)

  • 1. Cost advantages of oral drug therapy for managing cytomegalovirus disease.
    Somerville KT
    Am J Health Syst Pharm; 2003 Dec; 60(23 Suppl 8):S9-12. PubMed ID: 14686229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formulary considerations for drugs used to prevent cytomegalovirus disease.
    Pescovitz MD
    Am J Health Syst Pharm; 2003 Dec; 60(23 Suppl 8):S17-21. PubMed ID: 14686231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs and consequences of cytomegalovirus disease.
    Schnitzler MA
    Am J Health Syst Pharm; 2003 Dec; 60(23 Suppl 8):S5-8. PubMed ID: 14686228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New prophylactic treatment strategy for cytomegalovirus disease.
    Lake KD
    Am J Health Syst Pharm; 2003 Dec; 60(23 Suppl 8):S13-6. PubMed ID: 14686230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytomegalovirus antigenemia directed pre-emptive prophylaxis with oral versus I.V. ganciclovir for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, controlled trial.
    Singh N; Paterson DL; Gayowski T; Wagener MM; Marino IR
    Transplantation; 2000 Sep; 70(5):717-22. PubMed ID: 11003347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness model of cytomegalovirus management strategies in renal transplantation. Comparing valaciclovir prophylaxis with current practice.
    Mauskopf JA; Richter A; Annemans L; Maclaine G
    Pharmacoeconomics; 2000 Sep; 18(3):239-51. PubMed ID: 11147391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Similar reduction of cytomegalovirus DNA load by oral valganciclovir and intravenous ganciclovir on pre-emptive therapy after renal and renal-pancreas transplantation.
    Kalpoe JS; Schippers EF; Eling Y; Sijpkens YW; de Fijter JW; Kroes AC
    Antivir Ther; 2005; 10(1):119-23. PubMed ID: 15751769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incremental cost-effectiveness analysis of intravenous ganciclovir versus oral ganciclovir in the maintenance treatment of newly diagnosed cytomegalovirus retinitis in patients with AIDS.
    Rachlis A; Smaill F; Walker V; Hotchkies L; Jones A
    Pharmacoeconomics; 1999 Jul; 16(1):71-84. PubMed ID: 10539123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost of prophylaxis in the management of cytomegalovirus infection in solid organ transplant recipients.
    Oppenheimer F; Gonzalez-Molina M; Rubio M
    Clin Transplant; 2007; 21(4):441-8. PubMed ID: 17645702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delay of CMV infection in high-risk CMV mismatch lung transplant recipients due to prophylaxis with oral ganciclovir.
    Palmer SM; Grinnan DC; Diane Reams B; Steele MP; Messier RH; Duane Davis R
    Clin Transplant; 2004 Apr; 18(2):179-85. PubMed ID: 15016133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients.
    Winston DJ; Busuttil RW
    Transplantation; 2003 Jan; 75(2):229-33. PubMed ID: 12548129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-utility analysis of prophylactic treatment with oral ganciclovir for cytomegalovirus retinitis.
    Moore RD; Chaisson RE
    J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Sep; 16(1):15-21. PubMed ID: 9377120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ganciclovir. A pharmacoeconomic review of its use as intravenous or oral maintenance therapy in the management of cytomegalovirus retinitis in patients with AIDS.
    Perry CM; Davis R
    Pharmacoeconomics; 1997 Aug; 12(2 Pt 1):209-28. PubMed ID: 10169672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The economic impact of cytomegalovirus infection after liver transplantation.
    Kim WR; Badley AD; Wiesner RH; Porayko MK; Seaberg EC; Keating MR; Evans RW; Dickson ER; Krom RA; Paya CV
    Transplantation; 2000 Feb; 69(3):357-61. PubMed ID: 10706042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients.
    Cvetković RS; Wellington K
    Drugs; 2005; 65(6):859-78. PubMed ID: 15819597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined antiviral and immunoglobulin therapy as prophylaxis against cytomegalovirus infection after heart transplantation.
    Valenza M; Czer LS; Pan SH; Aleksic I; Freimark D; Harasty DA; Admon D; Barath P; Blanche C; Trento A
    J Heart Lung Transplant; 1995; 14(4):659-65. PubMed ID: 7578172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of intravenous ganciclovir followed by oral acyclovir with intravenous ganciclovir alone for prevention of cytomegalovirus and Epstein-Barr virus disease after liver transplantation in children.
    Green M; Kaufmann M; Wilson J; Reyes J
    Clin Infect Dis; 1997 Dec; 25(6):1344-9. PubMed ID: 9431375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial.
    Palmer SM; Limaye AP; Banks M; Gallup D; Chapman J; Lawrence EC; Dunitz J; Milstone A; Reynolds J; Yung GL; Chan KM; Aris R; Garrity E; Valentine V; McCall J; Chow SC; Davis RD; Avery R
    Ann Intern Med; 2010 Jun; 152(12):761-9. PubMed ID: 20547904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aciclovir or ganciclovir universal prophylaxis of cytomegalovirus infection in liver transplantation: an economic analysis.
    Leong RW; Smith DW; Garas G; Beaman JM; Mitchell AW; Heath DI; House AK; Jeffrey GP
    Intern Med J; 2004 Jul; 34(7):410-5. PubMed ID: 15271175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased incidence of cytomegalovirus infection in high-risk liver transplant recipients receiving valganciclovir prophylaxis versus ganciclovir prophylaxis.
    Shiley KT; Gasink LB; Barton TD; Pfeiffenberger P; Olthoff KM; Blumberg EA
    Liver Transpl; 2009 Aug; 15(8):963-7. PubMed ID: 19642123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.